Effective Date: 01/01/2023 I. Length of Authorization 1 Coverage will be provided for 6 months and may be renewed unless otherwise specified.• Use as adjuvant treatment of HER2-positive breast cancer is limited to 14 cycles (42 weeks total).II. Dosing Limits A. Quantity Limit (max daily...
Jorgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol. 2014;20(16):4526-4535. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth fact...